All In Biotech

Drug Trial Radar · NCT04633122

A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib

A Phase 2, Randomized, Multicenter, Open-label Study of DCC-2618 (Ripretinib, ZL-2307 ) vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Nov 25, 2020

Primary completion

Jul 20, 2022

Study completion Jul 20, 2022

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.

Conditions

  • Gastrointestinal Stromal Tumor(GIST)

Interventions

  • RipretinibDrug

    Oral kinase inhibitor

  • SunitinibDrug

    second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Approximately 12 months.

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • The General Hospital of Peking University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical Universty

    Chongqing, Chognqing, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

  • The Cancer Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The sixth Affiliated hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The 4th Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Affiliated Hospital of Haerbin MedicalUniversity

    Harbin, Heilongjiang, China

  • Union Hospital of HUST

    Wuhan, Hubei, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Fudan University Cancer Hospital

    Shanghai, Shanghai Municipality, China

  • Fudan University, Zhongshan Hospital

    Shanghai, Shanghai Municipality, China

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • The Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.